Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

drug-linker conjugates for ADC

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) ADC Cytotoxin (2) ADC Linker (7) Antibody-Drug Conjugates (ADCs) (5) Drug-Linker Conjugates for ADC (89) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1) Glucocorticoid Receptor (2) Isotope-Labeled Compounds (2) Microtubule/Tubulin (12) PSMA (1) STING (3) Topoisomerase (15)
By Research Areas:	Cancer (100) Inflammation/Immunology (1)
Click Chemistry:	DBCO (2) BCN (1) Azide (3) Alkynes (1)

104

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Drug-Linker Conjugates for ADC ADC Linker Antibody-Drug Conjugates (ADCs) PROTAC-Linker Conjugates for PAC Radionuclide-Drug Conjugates (RDCs) ADC Cytotoxin ADC Antibody Drug intermediate Drug isomer Target Protein Ligand-Linker Conjugates Drug Metabolite E3 Ligase Ligand-Linker Conjugates Ligands for Target Protein for PROTAC Ligands for E3 Ligase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156377

Biotin-PEG7-Maleimide	Drug-Linker Conjugates for ADC	Cancer
Biotin-PEG7-Maleimide is a biotinylation reagent that reacts with thiol groups (SH). Biotin-PEG7-Maleimide can be used as **Drug-Linker Conjugates for ADC**s .

HY-164239

NH2-PEG3-VC-PAB-MMAE	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
NH2-PEG3-VC-PAB-MMAE is a **drug-linker conjugate for ADC*, consisting of a cleavable ADC* linker (NH2-PEG3-VC-PAB) and a potent tubulin inhibitor Monomethyl auristatin E (MMAE) (HY-15162). NH2-PEG3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-13631O

(1R)-Deruxtecan	Drug-Linker Conjugates for ADC	Cancer
(1R)-Deruxtecan is a drug-linker conjugates for ADC .

HY-153428

GGGDTDTC-Mc-vc-PAB-MMAE	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
GGGDTDTC-Mc-vc-PAB-MMAE is a **Drug-Linker Conjugate for ADC, containing a tubulin** inhibitor Monomethyl auristatin E (MMAE, HY-15162) .

HY-164788

GGFG-PAB-MMAE	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
GGFG-PAB-MMAE (Comp 58054-1) is a **drug-linker conjugate for ADC*. GGFG-PAB-MMAE contains the ADC* linker (GGFG-PAB) and a potent tubulin polymerization inhibitor MMAE (HY-15162) .

HY-164837

VcMMAE-Eribulin	Drug-Linker Conjugates for ADC	Cancer
VcMMAE-Eribulin is a **Drug-Linker Conjugates for ADC*, which is composed of a linker* and a toxic molecule MMAE (HY-15162) (Microtubule inhibitor) and Eribulin (HY-13442) (Microtubule inhibitor). VcMMAE-Eribulin can be used for *ADC* synthesis.

HY-164835

VcMMAE-Deruxtecan	Drug-Linker Conjugates for ADC	Cancer
VcMMAE-Deruxtecan is a **Drug-Linker Conjugates for ADC*, which is composed of a linker* and a toxic molecule MMAE (HY-15162) (Microtubule inhibitor) and Exatecan (HY-13631) (DNA topoisomerase I inhibitor). VcMMAE-Deruxtecan can be used for *ADC* synthesis.

HY-164836

Deruxtecan-Eribulin	Drug-Linker Conjugates for ADC	Cancer
Deruxtecan-Eribulin is a **Drug-Linker Conjugates for ADC*, which is composed of a linker* and a toxic molecule Exatecan (HY-13631) (DNA topoisomerase I inhibitor) and Eribulin (HY-13442) (Microtubule inhibitor). Deruxtecan-Eribulin can be used for *ADC* synthesis.

HY-168285

LE01	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
LE01 is a **drug-linker conjugate for ADC*. LE01 contains a ADC* linker and a DNA topoisomerase I inhibitor DXd (HY-13631D). LE01 can be used to synthesize HER2-targeting ADC (HER2-LE01) .

HY-164829

Mal-C5-Gly-Gly-Phe-MMAE	Drug-Linker Conjugates for ADC	Cancer
Mal-C5-Gly-Gly-Phe-MMAE (Compound S5) is a **drug-linker conjugate for ADC*. Mal-C5-Gly-Gly-Phe-MMAE consists of MMAE (HY-15162) and a linker. Mal-C5-Gly-Gly-Phe-MMAE can be used for synthesis of ADCs* and for cancer research .

HY-164792

DBCO-PEG3-VC-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
DBCO-PEG3-VC-Exatecan (compound 25) is a **Drug-Linker Conjugate for ADC*. DBCO-PEG3-VC-Exatecan contains the ADC* linker (DBCO-PEG3-VC) and a DNA topoisomerase I inhibitor Exatecan (HY-13631) .

HY-163487

Puxitatug samrotecan drug-linker AZD8205 drug-linker	Drug-Linker Conjugates for ADC	Cancer
Puxitatug samrotecan drug-linker (AZD8205 drug-linker) is part of the anti-B7-H4 antibody-conjugated active molecule ADC (drug-linker conjugate for ADC). Puxitatug samrotecan drug-linker contains a degradable ADC linker and a topoisomerase I inhibitor Exatecan (HY-13631) .

HY-19813A

mDPR-Val-Cit-PAB-MMAE TFA	Drug-Linker Conjugates for ADC	Cancer
mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition ^{[1] ^.}

HY-155870

DL-01	Drug-Linker Conjugates for ADC	Cancer
DL-01 is a **drug-linker conjugates for ADC** that can be used for the synthesis of ADCs .

HY-155870A

DL-01 formic	Drug-Linker Conjugates for ADC	Cancer
DL-01 formic is a **drug-linker conjugates for ADC** that can be used for the synthesis of ADCs .

HY-148399

Mal-VC-PAB-PNP-CDN-A	Drug-Linker Conjugates for ADC	Cancer
Mal-VC-PAB-PNP-CDN-A is a **drug-Linker conjugates for ADC** .

HY-19697

Aminocaproyl-Val-Cit-PABC-MMAE	Drug-Linker Conjugates for ADC	Cancer
Aminocaproyl-Val-Cit-PABC-MMAE is an Drug-linker conjugate for ADC .

HY-160967

MC-GGFG-PAB-Exatecan	Drug-Linker Conjugates for ADC	Cancer
MC-GGFG-PAB-Exatecan (Compound 94) is a **drug-linker conjugate for ADC*, and can be used for synthesis of ADCs* .

HY-45672

Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH	ADC Linker	Cancer
Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC Linker that can be used to synthesize Drug-Linker Conjugates for ADC. Especially for the synthesis of Deruxtecan (HY-13631E), a toxic drug-linker conjugate .

HY-131451

Mc-Phe-Lys-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
Mc-Phe-Lys-PAB-MMAE (Compound 2) is a **drug-linker conjugate for ADC*, and can be used for synthesis of ADCs* .

HY-164705

Mal-Toxophore	Drug-Linker Conjugates for ADC	Cancer
Mal-Toxophore is a **drug-linker conjugate for ADC** and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-164759) .

HY-164707

MC7	Drug-Linker Conjugates for ADC	Cancer
MC7 is a **drug-linker conjugate for ADC** and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-402237) .

HY-W190944

DM1-MCC-PEG3-Biotin	Drug-Linker Conjugates for ADC	Cancer
DM1-MCC-PEG3-Biotin is a drug-linker conjugate for ADC.

HY-158349

Mal-Val-Ala-PAB-4-Abu(Me)-Dazostinag	Drug-Linker Conjugates for ADC STING	Cancer
Mal-Val-Ala-PAB-4-Abu(Me)-Dazostinag is a drug-linker conjugate for ADC.

HY-128896

Nitro-PDS-Tubulysin M	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
Nitro-PDS-Tubulysin M is a synthetic ADC drug-linker conjugate composed of the tubulin polymerization inhibitor Tubulysin M (an ADC Cytotoxin) and Nitro-PDS (an ADC linker).

HY-153032

Val-Ala-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
Val-Ala-PAB-MMAE is a Drug-Linker Conjugate for ADC, consisting of ADC linker (Val-Ala-PAB) and MMAE. MMAE is an effective inhibitor of tubulin.

HY-128959

MCC-Modified Daunorubicinol	Drug-Linker Conjugates for ADC	Cancer
MCC-Modified Daunorubicinol is a **drug-Linker conjugates for ADC*, which is composed of Modified Daunorubicinol (DNA topoisomerase II inhibitor) and MCC (ADC* linker) linked .

HY-157079

LP-6	Drug-Linker Conjugates for ADC	Cancer
LP-6 is a **Drug-Linker Conjugates for ADC*, and can be used for synthesis of ADCs. LP-6 consists of an Eg5 inhibitor and a linker* .

HY-49929

MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH	ADC Linker	Cancer
MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH is an ADC linker that can be combined with the cytotoxic Camptothecin (HY-16560) to form ADC-related drug-linker conjugates (Drug-Linker Conjugates for ADC ).MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH is conjugated to Camptothecin, which can further bind to the antibody Trastuzumab (HY-P9907) to form Antibody-Drug Conjugates (ADCs) .

HY-169324

APL-1092 Mal-Exo-EEVC-Exatecan	Drug-Linker Conjugates for ADC	Cancer
APL-1092 (Mal-Exo-EEVC-Exatecan) is a **drug-linker conjugate for ADC*, which contains Exatecan (HY-13631) (ADC* payload) and a linker .

HY-158348

m-PEG8-Lys(Mal)-Val-Ala-PAB-Ph-CO-Dazostinag	Drug-Linker Conjugates for ADC STING	Cancer
m-PEG8-Lys(Mal)-Val-Ala-PAB-Ph-CO-Dazostinag is a drug-linker conjugate for ADC.

HY-153069

GGFG-PAB-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
GGFG-PAB-Exatecan consists of an ADC toxin Exatecan (HY-13631) and a linker GGFG-PAB, and can be used as a drug-linker conjugate for the synthesis of ADC molecules .

HY-156687

GGFG-Eribulin	Drug-Linker Conjugates for ADC	Cancer
GGFG-Eribulin (Compound GGFG) is a **Drug-Linker Conjugates for ADC*. GGFG-Eribulin consists of the ADC* Cytotoxin Eribulin (HY-13442) and a linker. GGFG-Eribulin can be used for synthesis of ADCs .

HY-157284

Cys-mc-MMAE	Drug-Linker Conjugates for ADC	Cancer
Cys-mc-MMAE is a **Drug-Linker Conjugates for ADC*, and consists of Monomethyl auristatin E (HY-15162) and a linker. Cys-mc-MMAE can be used for synthesis of ADCs* .

HY-157407

Cyclooctyne-O-amido-PEG4-VC-PAB-Gly-Gly-NH-O-CO-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Cyclooctyne-O-amido-PEG4-VC-PAB-Gly-Gly-NH-O-CO-Exatecan is a drug-linker conjugate for ADC (ADC Cytotoxin: Exatecan) .

HY-164706

m-PEG6-Lys-Mal-Toxophore-quinoline	Drug-Linker Conjugates for ADC	Cancer
m-PEG6-Lys-Mal-Toxophore-quinoline is a **drug-linker conjugate for ADC** and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-164760) .

HY-158351

Mal-Val-Ala-PAB-NMe-CH2CH2-O-CO-Dazostinag	Drug-Linker Conjugates for ADC STING	Cancer
Mal-Val-Ala-PAB-NMe-CH2CH2-O-CO-Dazostinag is a drug-linker conjugate for ADC.

HY-78738

MC-Val-Cit-PAB	ADC Linker	Cancer
MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.

HY-15575G

VcMMAE MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .

HY-W250408

Fmoc-NMe-Val-Val-Dil-Dap-OH	Drug-Linker Conjugates for ADC	Cancer
Fmoc-NMe-Val-Val-Dil-Dap-OH is an intermediate for preparing drug-linker conjugate MC-MMAF, which can be used for synthesis of ADC molecule .

HY-156848

Fmoc-GGFG-DXd	Drug-Linker Conjugates for ADC	Cancer
Fmoc-GGFG-DXd is a **drug-linker conjugate for ADC*. Fmoc-GGFG-DXd contains a ADC* linker Fmoc-GGFG and a DNA topoisomerase I inhibitor DXd (HY-13631D) .

HY-136313

MC-VC-PAB-Tubulysin M	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
MC-vc-PAB-Tubulysin M is a synthetic ADC drug-linker conjugate composed of the tubulin polymerization inhibitor Tubulysin M (an ADC Cytotoxin) (HY-N7053) and MC-vc-PAB (a cleavable ADC linker) .

HY-153345

Glucocorticoid receptor agonist-1 phosphate(2,6-difluoro) Ala-Ala-Br	Drug-Linker Conjugates for ADC Glucocorticoid Receptor	Inflammation/Immunology
Glucocorticoid receptor agonist-1 phosphate(2,6-difluoro) Ala-Ala-Br is an **Drug-linker conjugates for ADC** that can be used as a reaction reagent for the synthesis of anti-CD40 antibody agent conjugates (ADCs) .

HY-153395

PH-HG-005-5	Drug-Linker Conjugates for ADC	Cancer
PH-HG-005-5 (compound 16c) is a derivative of SN-38 (HY-13704) and can be used as Drug-Linker Conjugates for ADC. PH-HG-005-5 can conjugate to targeting peptides for ADCs synthesis .

HY-153263

(Aminooxy)acetamide-Val-Cit-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
(Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthetic preparation of **drug-linker conjugates for ADC*. (Aminooxy)acetamide-Val-Cit-PAB-MMAE is conjugated* to polyamide via oxime bond formation to form MMAE polyamide conjugate. Then MMAE polyamide conjugate can be conjugated to Trastuzumab, to make ADC .

HY-153909

SMP-33693	Drug-Linker Conjugates for ADC	Cancer
SMP-33693 is a Drug-Linker Conjugate for ADC with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

HY-15575S

VcMMAE-d8 MC-Val-Cit-PAB-MMAE-d₈; mc-vc-PAB-MMAE-d₈	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a *agent-linker* conjugate for ADC** with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .

HY-160143

G3-VC-PAB-DMEA-Duocarmycin DM	Drug-Linker Conjugates for ADC	Cancer
G3-VC-PAB-DMEA-Duocarmycin DM (Compound LD-1) is a duocarmycin-based linker molecule that can be used for ADC preparation ..

HY-13631E

Deruxtecan Maximum Cited Publications 9 Publications Verification MC-GGFG-DXD	Drug-Linker Conjugates for ADC	Cancer
Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-160807

DBM-GGFG-NH-O-CO-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
DBM-GGFG-NH-O-CO-Exatecan is an inhibitor for topoisomerase I. DBM-GGFG-NH-O-CO-Exatecan can be used as a drug-linker conjugate for synthesis of ADC molecule .

Cat. No.	Product Name	Type

HY-15575G

VcMMAE (GMP) MC-Val-Cit-PAB-MMAE (GMP); mc-vc-PAB-MMAE (GMP)	Fluorescent Dye
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .

HY-45672G

Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (GMP)	Fluorescent Dye
Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-45672). Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC Linker that can be used to synthesize Drug-Linker Conjugates for ADC. Especially for the synthesis of Deruxtecan (HY-13631E), a toxic drug-linker conjugate .

HY-78738G

MC-Val-Cit-PAB (GMP)	Fluorescent Dye
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.

Cat. No.	Product Name	Type

HY-15575G

VcMMAE (GMP) MC-Val-Cit-PAB-MMAE (GMP); mc-vc-PAB-MMAE (GMP)	Biochemical Assay Reagents
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .

HY-45672G

Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (GMP)	Biochemical Assay Reagents
Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-45672). Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC Linker that can be used to synthesize Drug-Linker Conjugates for ADC. Especially for the synthesis of Deruxtecan (HY-13631E), a toxic drug-linker conjugate .

HY-78738G

MC-Val-Cit-PAB (GMP)	Biochemical Assay Reagents
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.

Cat. No.	Product Name	Target	Research Area

HY-164153

ADC Control Human IgG1-vcMMAE	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .

HY-164152

ADC Control Human IgG1-Deruxtecan (DAR 4)	Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

HY-164154

ADC Control Human IgG1-vcMMAF	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of *ADC* human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .

HY-P990027

Izeltabart	ADC Antibody	Cancer
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a **Drug-Linker Conjugates for ADC*), to synthesize IMGC936 (Antibody-Drug* Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .

Cat. No.	Product Name	Chemical Structure

HY-145989S

Aminobenzenesulfonic auristatin E-d8
Aminobenzenesulfonic auristatin E-d₈ is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1][2].

HY-15575S

VcMMAE-d8
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a *agent-linker* conjugate for ADC** with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .

HY-13631ES4

Deruxtecan-d5
Deruxtecan-d₅ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

HY-13631ES

Deruxtecan-d4
Deruxtecan-d₄ is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

Cat. No.	Product Name		Classification

HY-157407

Cyclooctyne-O-amido-PEG4-VC-PAB-Gly-Gly-NH-O-CO-Exatecan		Alkynes
Cyclooctyne-O-amido-PEG4-VC-PAB-Gly-Gly-NH-O-CO-Exatecan is a drug-linker conjugate for ADC (ADC Cytotoxin: Exatecan) .

HY-160893

PSMA-Val-Cit-PAB-Azide		Azide
PSMA-Val-Cit-PAB-Azide is a **drug-linker conjugate for ADC*. PSMA-Val-Cit-PAB-Azide contains the cleavable ADCs* linker (Val-Cit-PAB) and a novel small-molecule PSMA-targeted conjugate. It contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups .

HY-153962

SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3		Azide
SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a **Drug-Linker Conjugate for ADC*. SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 consists of the anti-cancer agent SN38 (HY-13704) and a linker* Lys(MMT)-PAB-oxydiacetamide-PEG8-N3 (HY-131157). SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 can be used for synthesis of ADCs . SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-164792

DBCO-PEG3-VC-Exatecan		DBCO
DBCO-PEG3-VC-Exatecan (compound 25) is a **Drug-Linker Conjugate for ADC*. DBCO-PEG3-VC-Exatecan contains the ADC* linker (DBCO-PEG3-VC) and a DNA topoisomerase I inhibitor Exatecan (HY-13631) .

HY-158199

BCN-HS-PEG2-bis(PNP)		BCN
BCN-HS-PEG2-bis(PNP) (Compound 62) is a p-nitrophenyl-containing ADC linker that can be used to further couple ADC cytotoxins with peptide linkers. BCN-HS-PEG2-bis(PNP) can conjugate with vc-PABC-MMAE (HY-15162) to form Drug-Linker Conjugates for ADC .

HY-164309

DBCO-PEG3-Glu-Val-Cit-PABC-MMAE		DBCO
DBCO-PEG3-Glu-Val-Cit-PABC-MMAE is a drug-linker conjugate for *ADC. DBCO-PEG3-Glu-Val-Cit-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (MMAE, HY-15162) and can be used for synthesis of dual-drug* ADC .

HY-153739

N3-PEG3-VC-PAB-MMAF		Azide
N3-PEG3-VC-PAB-MMAF (Comp T-88-5) is a drug-linker conjugate containing the ADC linker N3-PEG3-VC-PAB and the tubulin inhibitor MMAF . N3-PEG3-VC-PAB-MMAF is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: